| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell and Tumor Biology |
Departments of 1 Neurology and 2 Internal Medicine, Washington University School of Medicine, St. Louis, Missouri
Requests for reprints: David H. Gutmann, Department of Neurology, Box 8111, 660 South Euclid Avenue, St. Louis, MO 63110. Phone: 314-362-7379; Fax: 314-362-2388; E-mail: pouchera{at}neuro.wustl.edu.
Individuals with the tumor predisposition syndrome, neurofibromatosis 1 (NF1), are prone to development of nervous system tumors, including neurofibromas and pilocytic astrocytomas. Based on the ability of the NF1 gene product (neurofibromin) to function as a GTPase activating protein for RAS, initial biologically based therapies for NF1-associated tumors focused on the use of RAS inhibitors, but with limited clinical success. In an effort to identify additional targets for therapeutic drug design in NF1, we used an unbiased proteomic approach to uncover unanticipated intracellular signaling pathways dysregulated in Nf1-deficient astrocytes. We found that the expression of proteins involved in promoting ribosome biogenesis was increased in the absence of neurofibromin. In addition, Nf1-deficient astrocytes exhibit high levels of mammalian target of rapamycin (mTOR) pathway activation, which was inhibited by blocking K-RAS or phosphatidylinositol 3-kinase activation. This mTOR pathway hyperactivation was reflected by high levels of ribosomal S6 activation in both Nf1 mutant mouse optic nerve gliomas and in human NF1-associated pilocytic astrocytoma tumors. Moreover, inhibition of mTOR signaling in Nf1/ astrocytes abrogated their growth advantage in culture, restoring normal proliferative rates. These results suggest that mTOR pathway inhibition may represent a logical and tractable biologically based therapy for brain tumors in NF1.
Key Words: neurofibromatosis 1 RAS mTOR astrocytoma glioma
This article has been cited by other articles:
![]() |
C. Y. Zou, K. D. Smith, Q.-S. Zhu, J. Liu, I. E. McCutcheon, J. M. Slopis, F. Meric-Bernstam, Z. Peng, W. G. Bornmann, G. B. Mills, et al. Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor Mol. Cancer Ther., May 1, 2009; 8(5): 1157 - 1168. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Gutmann Using Neurofibromatosis-1 to Better Understand and Treat Pediatric Low-Grade Glioma J Child Neurol, October 1, 2008; 23(10): 1186 - 1194. [Abstract] [PDF] |
||||
![]() |
B. Hegedus, D. Banerjee, T.-H. Yeh, S. Rothermich, A. Perry, J. B. Rubin, J. R. Garbow, and D. H. Gutmann Preclinical Cancer Therapy in a Mouse Model of Neurofibromatosis-1 Optic Glioma Cancer Res., March 1, 2008; 68(5): 1520 - 1528. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Xu, F. A. Ismat, T. Wang, J. Yang, and J. A. Epstein NF1 Regulates a Ras-Dependent Vascular Smooth Muscle Proliferative Injury Response Circulation, November 6, 2007; 116(19): 2148 - 2156. [Abstract] [Full Text] [PDF] |
||||
![]() |
F.J. Wippold II, M. Lubner, R.J. Perrin, M. Lammle, and A. Perry Neuropathology for the Neuroradiologist: Antoni A and Antoni B Tissue Patterns AJNR Am. J. Neuroradiol., October 1, 2007; 28(9): 1633 - 1638. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. K. Sandsmark, H. Zhang, B. Hegedus, C. L. Pelletier, J. D. Weber, and D. H. Gutmann Nucleophosmin Mediates Mammalian Target of Rapamycin-Dependent Actin Cytoskeleton Dynamics and Proliferation in Neurofibromin-Deficient Astrocytes Cancer Res., May 15, 2007; 67(10): 4790 - 4799. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. C. Daginakatte and D. H. Gutmann Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth Hum. Mol. Genet., May 1, 2007; 16(9): 1098 - 1112. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Sharma, D. B. Mansur, G. Reifenberger, A. Perry, J. R. Leonard, K. D. Aldape, M. G. Albin, R. J. Emnett, S. Loeser, M. A. Watson, et al. Distinct Genetic Signatures among Pilocytic Astrocytomas Relate to Their Brain Region Origin Cancer Res., February 1, 2007; 67(3): 890 - 900. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Yang, E. Jackson, B. M. Woerner, A. Perry, D. Piwnica-Worms, and J. B. Rubin Blocking CXCR4-Mediated Cyclic AMP Suppression Inhibits Brain Tumor Growth In vivo Cancer Res., January 15, 2007; 67(2): 651 - 658. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Lavery, V. Hall, J. C. Yager, A. Rottgers, M. C. Wells, and M. Stern Phosphatidylinositol 3-Kinase and Akt Nonautonomously Promote Perineurial Glial Growth in Drosophila Peripheral Nerves J. Neurosci., January 10, 2007; 27(2): 279 - 288. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Walker, A. V. Tchoudakova, P. T. McKenney, S. Brill, D. Wu, G. S. Cowley, I. K. Hariharan, and A. Bernards Reduced growth of Drosophila neurofibromatosis 1 mutants reflects a non-cell-autonomous requirement for GTPase-Activating Protein activity in larval neurons Genes & Dev., December 1, 2006; 20(23): 3311 - 3323. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Charest, E. W. Wilker, M. E. McLaughlin, K. Lane, R. Gowda, S. Coven, K. McMahon, S. Kovach, Y. Feng, M. B. Yaffe, et al. ROS Fusion Tyrosine Kinase Activates a SH2 Domain-Containing Phosphatase-2/Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Signaling Axis to Form Glioblastoma in Mice. Cancer Res., August 1, 2006; 66(15): 7473 - 7481. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Li, A. M. Munchhof, H. A. White, L. E. Mead, T. R. Krier, A. Fenoglio, S. Chen, X. Wu, S. Cai, F.-C. Yang, et al. Neurofibromin is a novel regulator of RAS-induced signals in primary vascular smooth muscle cells Hum. Mol. Genet., June 1, 2006; 15(11): 1921 - 1930. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Munchhof, F. Li, H. A. White, L. E. Mead, T. R. Krier, A. Fenoglio, X. Li, J. Yuan, F.-C. Yang, and D. A. Ingram Neurofibroma-associated growth factors activate a distinct signaling network to alter the function of neurofibromin-deficient endothelial cells Hum. Mol. Genet., June 1, 2006; 15(11): 1858 - 1869. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Dasgupta, Y. Yi, B. Hegedus, J. D. Weber, and D. H. Gutmann Cerebrospinal Fluid Proteomic Analysis Reveals Dysregulation of Methionine Aminopeptidase-2 Expression in Human and Mouse Neurofibromatosis 1-Associated Glioma Cancer Res., November 1, 2005; 65(21): 9843 - 9850. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |